ライフサイエンスコーパス: cell transplant

1 engineered T cells 2 d after autologous stem cell transplant.

2 ion after unrelated-donor hematopoietic stem cell transplant.

3 in lymphoma received chemotherapy and a stem cell transplant.

4 e treatment or autologous or allogeneic stem-cell transplant.

5 to identify an etiology, 6 weeks after stem cell transplant.

6 free without a consolidative allogeneic stem cell transplant.

7 ib treatment and high-dose melphalan in stem cell transplant.

8 ortality after allogeneic hematopoietic stem cell transplant.

9 ortality after allogeneic hematopoietic stem cell transplant.

10 tion in first remission with autologous stem cell transplant.

11 ion is a significant complication after stem cell transplant.

12 3%) to lenalidomide; 39 (59%) had prior stem cell transplant.

13 hal complication of allogeneic hematopoietic cell transplant.

14 ne of these viruses after hematopoietic stem cell transplant.

15 rior methotrexate, and prior autologous stem-cell transplant.

16 ts (range 1-11); 18 (38%) had undergone stem-cell transplant.

17 ponses among the 18 patients with prior stem-cell transplant.

18 re not planned for immediate autologous stem-cell transplant.

19 reatment that included an HIV-resistant stem cell transplant.

20 um-based chemotherapy before autologous stem cell transplant.

21 secutive patients undergoing allogeneic stem cell transplant.

22 tic progenitor cells in preparation for stem cell transplant.

23 ical malignancies and the recipients of stem-cell transplant.

24 development of allogeneic hematopoietic stem cell transplant.

25 s, particularly those who have received stem cell transplants.

26 omide), and 76% had received autologous stem-cell transplants.

27 :CLEC2D) interactions in human hematopoietic cell transplants.

28 on in recipients of allogeneic hematopoietic-cell transplants.

29 ressive therapies and/or solid organ or stem cell transplants.

30 of CMV events in recipients of hematopoietic-cell transplants.

31 to both solid organ and haematopoietic stem cell transplants.

32 ronic administration of immunosuppression in cell transplants.

33 id formation in type 2 diabetes and in islet cell transplants.

34 reatment of blood cancers with hematopoietic cell transplants.

35 itution in recipients of haploidentical stem-cell transplants.

36 s host disease in matched or mismatched stem cell transplants.

37 educe the rate of relapse in allogeneic stem cell transplants.

38 aftment rates, with similar numbers of CD34+ cells transplanted.

39 h patients should receive an allogeneic stem cell transplant?

40 ncrystalline LCPT, of whom 11 underwent stem cell transplant, 16 received chemotherapy only, and nine

41 in adults receiving allogeneic hematopoietic cell transplants (1999-2005) from HLA-identical sibling

42 red with patients who did not receive a stem-cell transplant (42% v 16%).

43 had undergone autologous hematopoietic stem-cell transplant 50 to 70 days earlier.

44 guide migration and differentiation of stem cell transplants after brain injury.

45 Autologous hematopoietic cell transplant (AHCT) for HIV-infected patients is larg

46 Allogeneic hematopoietic cell transplant (allo-HCT) can be curative for certain h

47 lity to distinguish allogeneic hematopoietic cell transplant (allo-HCT) recipients at risk for cytome

48 on a cohort of 237 allogeneic hematopoietic cell transplant (allo-HCT) recipients, that can predict

49 Most clinical allogeneic hemopoietic cell transplants (alloHCT) are now performed using reduc

50 arting treatment achieved hematopoietic stem cell transplant (alloHSCT) compared with 46% in the imat

51 omplication of allogeneic hematopoietic stem cell transplant (alloHSCT), underscoring the need to fur

52 do not appear to require an allogeneic stem cell transplant (alloSCT) if they achieve a good respons

53 mobilized stem cells all accepted their stem cell transplant and became tolerant to the VCA.

54 Risk-adapted stem cell transplant and consolidation with novel agents may

55 nts in need of allogeneic hematopoietic stem cell transplant and has recruited millions of volunteers

56 s (P = .005 vs allogeneic hematopoietic stem cell transplant and P = .048 vs others).

57 , persons with autologous hematopoietic stem cell transplant and those without graft-versus-host dise

58 n additional 300 patients who underwent stem cell transplant and were enrolled on multicentre clinica

59 of the children received hematopoietic stem cell transplants and all showed poor graft function with

60 biologic therapy such as hematopoietic stem cell transplants and mesenchymal cell infusions.

61 ibody is associated with early graft loss of cell transplants and reduced long-term survival of solid

62 consolidative hematopoietic allogeneic stem cell transplant, and 9 (9% of all enrolled patients) rem

63 iver, bowel, pancreas, heart, lung, and stem-cell transplant, and blood transfusion.

64 lds of solid organ transplant, hematopoietic cell transplant, and organ donation.

65 Studies of critically ill, oncologic or stem cell transplant, and solid organ transplant patients sho

66 mmunosuppressive drugs, 13 had received stem cell transplants, and 7 were infected with human immunod

67 nsfusions, bone marrow or hematopoietic stem cell transplants, and experimental pharmacologic chapero

68 Recipients of allogeneic hematopoietic stem cell transplant appear to have the highest risk of morta

69 for both solid organ and hematopoietic stem cell transplant applications.

70 e field of hematology, as hematopoietic stem cell transplants are already commonplace in clinics arou

71 The majority of allogeneic stem cell transplants are currently undertaken using G-CSF mo

72 an adequate blood supply for the survival of cell transplants are major hurdles that need to be overc

73 Patients who receive hematopoietic cell transplants are usually immunosuppressed for extend

74 on emission tomography or hematopoietic stem cell transplant as independent prognostic factors for ou

75 e-ferumoxytol-positive macrophages into stem cell transplants, as visualized with IVM and histopathol

76 In addition, pre-autologous stem cell transplant (ASCT) (18)FDG-PET response to SLT predi

77 ients initially treated with autologous stem cell transplant (ASCT) at Mayo Clinic.

78 dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) may provide an alternative to add

79 Utilization of autologous stem cell transplant (ASCT) was similar across all periods, a

80 alvage chemotherapy (SC) and autologous stem cell transplant (ASCT).

81 actory myeloma undergoing an autologous stem-cell transplant (ASCT).

82 g cytarabine, rituximab, and autologous stem-cell transplant (ASCT).

83 halan with low-dose TBI after haplocord stem cell transplant assures good engraftment and leads to ac

84 The addition of an autologous stem cell transplant before cART withdrawal alters viral dyna

85 Unexpectedly, MGE cells transplanted before injury prevented the developme

86 mes of patients who underwent haplocord stem cell transplant between May 2013 and March 2015 and who

87 or the use of RIC regimens in all adult stem cell transplant candidates with acute leukemia in remiss

88 ent admissions with a non-hematopoietic stem cell transplant cohort and excluded solid-organ transpla

89 ortality was 32.9% in non-hematopoietic stem cell transplant cohort, which was similar to autologous

90 hen compared with the non-hematopoietic stem cell transplant cohort.

91 imaging of donor-matched and mismatched stem cell transplants demonstrated decreased signal intensity

92 esis that selective GABA agonists as well as cell transplant-derived GABA are antipruritic against ac

93 Allogeneic stem cell transplants differ from conventional tissue transpl

94 Allogeneic cells transplanted directly to the liver do not enjoy im

95 ority of patients in need of a hematopoietic-cell transplant do not have a matched related donor.

96 high-dose chemotherapy with autologous stem-cell transplant failure were included.

97 blative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differenti

98 n a patient who received a heterologous stem cell transplant for acquired immunodeficiency syndrome-r

99 230 subjects receiving a first hematopoietic cell transplant from a human leukocyte antigen-matched s

100 icient SCID (ADA-SCID) is hematopoietic stem cell transplant from an HLA-matched sibling donor, altho

101 received a first myeloablative hematopoietic-cell transplant from an unrelated cord-blood donor (140

102 gh) CTLs) in 53/115 CMV IgG(+) patients stem cell transplanted from CMV IgG(+) donors.

103 two patients who received hematopoietic stem cell transplants from 2004 through 2008 at the Universit

104 C2 positive recipients of hematopoietic stem cell transplants from 2DS1 positive donors.

105 es by promoting cell survival and protecting cell transplants from immune rejection.

106 itive recipients of allogeneic hematopoietic-cell transplants from matched related or unrelated donor

107 with AML who had received hematopoietic stem-cell transplants from unrelated donors matched for HLA-A

108 Most importantly, NKG2C(+) NK cells transplanted from seropositive donors exhibit heig

109 Recipients of olfactory mucosal cell transplants gained significantly better fore-hind c

110 ents with crystalline LCPT treated with stem cell transplant had stable or improved kidney function,

111 undergoing haploidentical hematopoietic stem cell transplant (haplo-HSCT) without the risk for uncont

112 Allogeneic hematopoietic stem cell transplant (hazard ratio [HR] = 2.28; 95% confidenc

113 a formidable challenge to the hematopoietic cell transplant (HCT) and kidney transplant fields.

114 yndrome (BOS) after allogeneic hematopoietic cell transplant (HCT) conferred nearly universal mortali

115 man herpesvirus 6 (ciHHV-6) in hematopoietic cell transplant (HCT) donors or recipients confounds mol

116 who receive an unrelated donor hematopoietic cell transplant (HCT) for the treatment of blood disorde

117 al virus (RSV) pneumonia after hematopoietic cell transplant (HCT) is associated with severe morbidit

118 tory virus infections prior to hematopoietic cell transplant (HCT) is difficult.

119 therapy (HDIT) with autologous hematopoietic cell transplant (HCT) may, in contrast, induce sustained

120 omosome (HY-Abs) develop after hematopoietic cell transplant (HCT) of male recipients with female don

121 CD4(+) </=200; autologous hematopoietic stem-cell transplant (HCT) or allogeneic-HCT recipients.

122 lasia (MDS), and in allogeneic hematopoietic cell transplant (HCT) recipients (early, until day 40; l

123 ults of MVA in allogeneic hematopoietic stem cell transplant (HCT) recipients and Triplex in healthy

124 lid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients at a single center over

125 disseminated viral disease in hematopoietic cell transplant (HCT) recipients but does not lead to re

126 5-specific T cells can protect hematopoietic cell transplant (HCT) recipients from CMV complications.

127 integrated HHV-6 (iciHHV-6) in hematopoietic cell transplant (HCT) recipients is unclear.

128 e respiratory disease in adult hematopoietic cell transplant (HCT) recipients.

129 fe-threatening complication in hematopoietic cell transplant (HCT) recipients.

130 with significant mortality in hematopoietic cell transplant (HCT) recipients.

131 a surveillance method for hematopoietic stem cell transplant (HCT) recipients.

132 ase than seasonal influenza in hematopoietic cell transplant (HCT) recipients.

133 eatment trials are lacking for hematopoietic cell transplant (HCT) recipients.

134 apsed CLL following allogeneic hematopoietic cell transplant (HCT) who subsequently received ibrutini

135 logic malignancy or undergoing hematopoietic cell transplant (HCT).

136 ies (HMs) and in recipients of hematopoietic cell transplant (HCT).

137 and symptom burden during hematopoietic stem-cell transplant (HCT).

138 s of both solid-organ and hematopoietic stem cell transplant (HCT).

139 eloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic str

140 atients who receive allogeneic hematopoietic cell transplants (HCTs), and the skin is the most common

141 after high-dose therapy and autologous stem-cell transplant (HDT/ASCT) for patients with relapsed or

142 livery of potent immune suppressor cells for cell transplants holds great clinical application potent

143 etes and contributes to the failure of islet cell transplants, however the mechanisms of IAPP-induced

144 y and a majority received hematopoietic stem cell transplant (HSCT) (11/13).

145 missions for induction or hematopoietic stem-cell transplant (HSCT) from 2006 to 2014 was selected.

146 Autologous hematopoietic stem cell transplant (HSCT) has been effective in treating ot

147 The field of hematopoietic stem cell transplant (HSCT) has made ground-breaking progress

148 Hematopoietic stem cell transplant (HSCT) is the only cure for sickle cell

149 Autologous and allogeneic hematopoietic stem cell transplant (HSCT) patients are susceptible to pulmo

150 ction in adult allogeneic hematopoietic stem-cell transplant (HSCT) patients.

151 the pediatric allogeneic hematopoietic stem cell transplant (HSCT) population is unknown.

152 V-seronegative allogeneic hematopoietic stem cell transplant (HSCT) recipient is generally accepted.

153 irus (CMV) viral loads in hematopoietic stem cell transplant (HSCT) recipients are typically monitore

154 he risk of skin cancer in hematopoietic stem-cell transplant (HSCT) recipients has not been extensive

155 2 study in 50 allogeneic hematopoietic stem cell transplant (HSCT) recipients who received donorderi

156 ed in >/=9% of allogeneic hematopoietic stem cell transplant (HSCT) recipients, in whom it can cause

157 tality in solid organ and hematopoietic stem cell transplant (HSCT) recipients.

158 atients and especially in hematopoietic stem cell transplant (HSCT) recipients.

159 tency and reactivation in hematopoietic stem cell transplant (HSCT) recipients.

160 d mortality in allogeneic hematopoietic stem cell transplant (HSCT) recipients.

161 , such as solid organ and hematopoietic stem cell transplant (HSCT) recipients.

162 atients with leukemia and hematopoietic stem cell transplant (HSCT) recipients.

163 uclear cells (PBMCs) from hematopoietic stem cell transplant (HSCT) recipients.

164 rgan transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients.

165 fectious complications in hematopoietic stem cell transplant (HSCT) recipients.

166 nts, including allogeneic hematopoietic stem cell transplant (HSCT) recipients.

167 eatment in the allogeneic hematopoietic stem cell transplant (HSCT) setting.

168 Hematopoietic stem cell transplant (HSCT)-associated thrombotic microangiop

169 interest in the field of hematopoietic stem cell transplant (HSCT).

170 organ transplant (SOT) or hematopoietic stem cell transplant (HSCT).

171 d or unrelated allogeneic hematopoietic stem cell transplant (HSCT).

172 uble umbilical cord blood hematopoietic stem cell transplant (HSCT).

173 ize cerebral disease is a hematopoietic stem cell transplant (HSCT).

174 ophy after treatment with hematopoietic stem cell transplant (HSCT).

175 ortality after allogeneic hematopoietic stem cell transplant (HSCT).

176 frequent complications of hematopoietic stem cell transplant (HSCT).

177 other than myeloablative hematopoietic stem cell transplant (HSCT); however, relapse remains a major

178 ections often occur after hematopoietic stem cell transplant (HSCT); vaccination is important for pre

179 ration site analysis in a hematopoietic stem cell-transplanted humanized mouse model.

180 Hematopoietic stem cell transplant, if performed early in metachromatic leu

181 2 treatments (range, 1-6), including a stem cell transplant in 105 patients (75%), were administered

182 cured following a delta32/delta32 CCR5 stem cell transplant in 2007 revealed no antibodies against p

183 sible, then high-dose chemotherapy with stem cell transplant in an experienced center is a reasonable

184 age chemotherapy followed by autologous stem cell transplant in chemosensitive disease.

185 nt; 25 patients underwent an allogeneic stem cell transplant in first CR and were excluded, leaving 7

186 Allogeneic stem cell transplant in second remission is the only curative

187 suggests that the rejection of similar stem cell transplants in humans will be dependent upon the pr

188 licable to noninvasively monitor therapeutic cell transplants in multiple tissues.

189 ons could reduce the number of hematopoietic cell transplants in patients with AML by 20-25% while ma

190 n contrast, Sharpin(cpdm) mammary epithelial cells transplanted in vivo into wild-type stroma, fully

191 he Lancet of embryonic-stem-cell-derived RPE cell transplants indicate no serious adverse outcomes an

192 KIR/HLA mismatched hematopoietic stem cell transplants induce alloreactive NK cells, which pre

193 igration of nmMYLK(-/-) microglia (2 x 10(5) cells transplanted into corpus callosum) compared with W

194 ovides the first description of hESC-derived cells transplanted into human patients.

195 AGM region cells transplanted into immunodeficient mice provide lon

196 Unexpectedly, cells transplanted into naive spinal cord prevented the

197 into old recipients; conversely, young beta-cells transplanted into old mice decrease their replicat

198 ave increased replication rate compared with cells transplanted into old recipients; conversely, youn

199 Furthermore, human CD34(+) cells transplanted into ossicle-bearing mice engrafted a

200 Finally, YT cells transplanted into severe combined immunodeficiency

201 w that for encapsulated rat pancreatic islet cells transplanted into streptozotocin-treated diabetic

202 Enteric neural cells transplanted into the bowel give rise to multiple

203 In addition, we demonstrate that old beta-cells transplanted into young recipients have increased

204 e their replication rate compared with young cells transplanted into young recipients.

205 The role of allogeneic hematopoietic stem cell transplant is less clear but may be useful in selec

206 In myelofibrosis, stem cell transplant is the current treatment of choice for g

207 ansfer of human peripheral blood mononuclear cells, transplanted LEA-tg ICCs were completely protecte

208 ia-like" regimen followed by allogeneic stem-cell transplant may be advisable; addition of a tyrosine

209 ad received an allogeneic hematopoietic stem cell transplant (median, 61 [interquartile range {IQR},

210 s of hematopoiesis and develop hematopoietic cell transplant methodology.

211 We used a Panc02 pancreatic tumor cell transplant model in diet-induced obese (DIO) C57BL/

212 ssociated chemokine receptors in murine stem cell transplant models.

213 own postnatal mice-plus syngeneic fibroblast cell-transplant models-we demonstrate that the regenerat

214 y Hodgkin lymphoma following autologous stem cell transplant (N = 102) after a median observation per

215 66; HR = 0.66; P = .001) and autologous stem cell transplant (n = 273; HR = 0.55; P = .004) were inde

216 2.39-6.07) and autologous hematopoietic stem cell transplant (odds ratio, 1.28; 95% CI, 1.06-1.53) re

217 l mortality in allogeneic hematopoietic stem cell transplant (odds ratio, 3.81; 95% CI, 2.39-6.07) an

218 de effects of lifetime immunosuppression for cell transplants often outweigh the benefits; therefore,

219 m surgical biopsies that include mesenchymal cells transplanted on biodegradable scaffolds.

220 We found that primary ALL cells transplanted onto nonobese diabetic/severe combine

221 a who previously received an autologous stem cell transplant or two previous multiagent chemotherapy

222 Mice receiving 5-LO-deficient cell transplant or zileuton treatment had prolonged surv

223 ion could potentially lead to improved islet cell transplant outcomes.

224 labeled MSCs enabled serial MR monitoring of cell transplants over 14 days.

225 conditioning regimen for hematopoietic stem cell transplant (P = .002), and the cumulative dose of c

226 splant recipients and one hematopoietic stem-cell transplant patient with positive A. calidoustus cul

227 entified all hematologic malignancy and stem cell transplant patients diagnosed with proven mucormyco

228 infused 12 haploidentical hematopoietic stem cell transplant patients with increasing numbers of allo

229 dds of mortality than non-hematopoietic stem cell transplant patients.

230 n lymphocyte reconstitution in hematopoietic cell transplant patients.

231 ificantly higher than non-hematopoietic stem cell transplant patients.

232 ng and in solid-organ and hematopoietic stem cell transplant patients.

233 ng patients who received blood-building stem cell transplants, patients with chronic granulomatous di

234 3 unrelated marrow and peripheral blood stem cell transplants performed from 1995 to 2007 for treatme

235 Among patients with hematopoietic stem cell transplant, persons with autologous hematopoietic s

236 idomide/pomalidomide, double autologous stem cell transplant plus bortezomib, or combination of immun

237 dysplastic syndromes, and hematopoietic stem cell transplant populations has been evaluated in recent

238 The use of tacrolimus in our islet-cell transplant protocol caused an initial 20% reduction

239 rate, and metastasis compared with cortical cells-transplanted rats.

240 egionnaires' disease in a hematopoietic stem cell transplant recipient caused by this organism is des

241 ection was diagnosed in a hematopoietic stem cell transplant recipient during conditioning regimen.

242 liver failure in an adult hematopoietic stem cell transplant recipient.

243 was similar to autologous hematopoietic stem cell transplant recipients (30.1%) and those who did not

244 ant recipients (n = 197), 0% to 5.8% in stem-cell transplant recipients (n = 103), and 11.2 to 15.2%

245 Autologous hematopoietic stem cell transplant recipients and those who do not develop

246 Hematopoietic stem cell transplant recipients are more likely to be immunoc

247 Hematopoietic stem cell transplant recipients are more likely to develop se

248 a cluster of fatal toxoplasmosis among stem cell transplant recipients at 2 hospitals, surveillance

249 unit knockout mice, we demonstrate that stem cell transplant recipients lacking the ability to genera

250 reventing RSV LRTIs in 50 hematopoietic stem cell transplant recipients or patients with hematologic

251 t cytomegalovirus infection in hematopoietic cell transplant recipients provided initial data on the

252 fects of GvHD itself, all serve to make stem cell transplant recipients vulnerable to disease from en

253 uency of severe sepsis in hematopoietic stem cell transplant recipients was five times higher when co

254 Twenty-four hematopoietic stem cell transplant recipients were enrolled sequentially in

255 ion therapy or allogeneic hematopoietic stem cell transplant recipients were randomized (1:1 ratio) t

256 in subsequent admissions, hematopoietic stem cell transplant recipients with graft-versus-host diseas

257 as detected in 9 of 79 (11.4%) hematopoietic cell transplant recipients with influenza, and was less

258 es and mortality in allogeneic hematopoietic cell transplant recipients with invasive pulmonary asper

259 We compared outcomes of hematopoietic stem cell transplant recipients with severe sepsis during eng

260 A total of 21,898 hematopoietic stem cell transplant recipients with severe sepsis were ident

261 patients (renal transplant recipients, stem cell transplant recipients, and congenitally infected ch

262 omen, neutropenic hosts, solid-organ or stem cell transplant recipients, and patients receiving tumor

263 t cohorts of solid-organ and allogeneic stem-cell transplant recipients, respectively.

264 taneous malignant neoplasms in hematopoietic cell transplant recipients, this population should be ed

265 ality of severe sepsis in hematopoietic stem cell transplant recipients.

266 or survival in allogeneic hematopoietic stem cell transplant recipients.

267 ication codes to identify hematopoietic stem cell transplant recipients.

268 asive aspergillosis among hematopoietic stem cell transplant recipients.

269 gical malignancies and in hematopoietic stem cell transplant recipients.

270 ral control in allogeneic hematopoietic stem cell transplant recipients.

271 gement of solid organ and hematopoietic stem cell transplant recipients.

272 strategy for mucormycosis in organ and stem cell transplant recipients.

273 sus-host disease in allogeneic hematopoietic cell transplant recipients.

274 dose-range-finding prophylaxis study in stem-cell transplant recipients.

275 (cGVHD) after allogeneic hematopoietic stem cell transplant reflects a complex immune response resul

276 JMML relies on allogeneic hematopoietic stem cell transplant, relapse is the most frequent cause of t

277 een applied for decades, outcomes of somatic cell transplants remain disappointing, presumably due to

278 CMV pneumonia in recipients of hematopoietic cell transplant remains a significant challenge.

279 f stem cells from the BM and autologous stem cell transplant rescued RIL in mice.

280 linical factors, induction therapy, and stem cell transplant (SCT) on the outcomes of 311 patients wi

281 vention and treatment of postallogeneic stem cell transplant (SCT) relapse.

282 R patients, 16 received a consolidative stem cell transplant (SCT) with median PFS not reached.

283 tients who relapse following autologous stem cell transplant (SCT), multiple treatment options are av

284 < 0.0001) and not undergoing allogeneic stem cell transplant (SCT, p = 0.0005) predicted poor overall

285 g risk in patients receiving allogeneic stem cell transplants (SCTs) or chemotherapy but not in those

286 Hematopoietic stem cell transplant therapy is limited by pulmonary infectio

287 ronal and retinal development and ultimately cell-transplant therapy.

288 nts in 3 medical centers using hematopoietic cell transplants to establish mixed or complete chimeris

289 ) outbreak in a hematology-oncology and stem cell transplant unit.

290 Allogeneic hematopoietic stem cell transplant was offered to selected patients in firs

291 Salvage high-dose chemotherapy plus a stem-cell transplant was required in six (6%) patients in the

292 However, by using cell transplants, we demonstrate that prechordal plate m

293 ine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

294 recipients of allogeneic hematopoietic stem cell transplants who underwent GBCA-enhanced MR imaging

295 ents who require an allogeneic hematopoietic cell transplant will have an HLA-matched sibling donor.

296 biopsy in patients who have undergone a stem cell transplant with eruptions on the head and neck.

297 detection of innate immune responses to stem cell transplants with magnetic resonance (MR) imaging.

298 in vivo and can be used for tracking of stem cell transplants with MR imaging.

299 detection of innate immune responses to stem cell transplants with MR imaging.

300 recipients of allogeneic hematopoietic stem cell transplant, with their infections caused by five Le